LATS1/2 Kinase (Ser909/872): Dual‑Function Regulator Balancing Intestinal Stem‑Cell Fate and Wnt‑Pathway Output

Background: Interconnected Signalling Circuits Governing Intestinal Epithelial Homeostasis

The mammalian intestinal epithelium represents one of the most rapidly self‑renewing tissue systems inside the organism. Its constant turnover strictly depends on finely‑tuned intestinal stem‑cell (ISC) regulatory programmes controlling self‑renewal, proliferation and cell‑fate differentiation.

The canonical Wnt/β‑catenin signalling cascade acts as the primary driving force sustaining ISC stem‑ness and promoting crypt‑epithelial‑cell proliferation. Meanwhile, the evolutionarily‑conserved Hippo signalling pathway governs organ‑size control, tissue‑repair responses and oncogenic transformation across multiple tissue contexts. Core Hippo kinases LATS1 and LATS2 exert biological effects by phosphorylating and functionally restraining downstream transcriptional co‑activators YAP and TAZ. Nevertheless, mechanistic details describing how LATS1/2 modulate ISC behaviour and crosstalk with Wnt cascades remained incompletely characterized for extended research periods.

Contrasting Phenotypes Observed in Intestinal‑Epithelium‑Specific Lats1/2 Conditional‑Knock‑Out Models

Genetically‑engineered conditional mouse models were generated to dissect LATS1/2 physiological roles within intact intestinal tissue. Epithelial‑specific deletion of Lats1 together with Lats2 triggers measurable loss of functional intestinal stem‑cell populations, a phenotype which resembles experimental outcomes caused by impaired Wnt‑pathway activity. Paradoxically, Lats1/2‑deficient intestinal tissue simultaneously displays prominent crypt‑zone expansion independent of canonical Wnt‑signalling input.

These seemingly contradictory experimental observations point toward dual regulatory properties for LATS1/2 within intestinal homeostasis. On one hand, LATS1/2 kinase activity sustains ISC stem‑cell identity and preserves physiological Wnt‑signalling magnitude. On the other hand, LATS1/2 restricts pathological over‑proliferation by constraining alternative pro‑proliferative molecular programmes. LATS1/2 therefore operates as a bidirectional molecular rheostat balancing stem‑cell maintenance and crypt‑hyperplasia risk within intestinal epithelial compartments.

Distinct Molecular Mechanisms Underlying Dual LATS1/2‑Mediated Regulatory Outputs

Genetic epistasis assays and proteomic profiling uncovered two separable downstream effector cascades mediated by YAP‑TAZ transcriptional complexes.

The first regulatory branch executes YAP‑TAZ‑dependent yet TEAD‑transcription‑factor‑independent repression upon Wnt‑target‑gene transcription. Upon LATS1/2 loss‑of‑function, de‑phosphorylated YAP‑TAZ molecules translocate into cell nuclei and physically associate with transcriptional co‑repressor TLE (Groucho). TLE protein forms inhibitory complexes together with TCF transcription factors, thereby dampening Wnt‑driven target‑gene expression programmes. This molecular event contributes to ISC exhaustion observed within Lats1/2‑knock‑out intestinal tissue specimens.

The second regulatory axis relies on canonical YAP‑TAZ‑TEAD transcriptional‑complex assembly to drive crypt‑cell‑proliferation phenotypes. TEAD transcriptional‑activity is modulated by palmitoylation post‑translational modification. Reversible small‑molecule compounds interfering with TEAD palmitoylation can attenuate Wnt‑independent hyper‑proliferation and lower oncogenic Myc transcript abundance in Lats1/2‑deficient experimental systems. When applied to Apc‑mutant pre‑clinical intestinal‑tumour mouse‑models, simultaneous LATS‑functional‑loss together with TEAD‑inhibition effectively suppresses neoplastic over‑growth, offering exploratory intervention directions for intestinal‑tumour‑oriented basic‑research.

Biological Significance of LATS1/2 Ser909/Ser872 Activation‑Loop Phosphorylation

LATS‑kinase catalytic capacity is governed by phosphorylation events taking place within conserved activation‑loop polypeptide segments. LATS1 Ser909 and LATS2 Ser872 residues represent functionally‑critical phospho‑sites catalysed by upstream MST1‑MST2‑SAV1 kinase complexes. Detecting phosphorylation status at these two sites furnishes direct biochemical read‑outs reflecting endogenous Hippo‑pathway kinase‑cascade activation magnitude.

Site‑specific phospho‑LATS1/2 immunodetection reagents support multiple investigative angles for intestinal‑biology basic‑research. Researchers can trace Hippo‑signalling dynamic shifts under homeostatic, inflammatory or neoplastic tissue conditions. These antibody tools also help map molecular‑crosstalk between Wnt, inflammatory‑response and nutrient‑sensing input signals converging onto Hippo kinase cascades. Furthermore, phospho‑LATS1/2 immunoblot signals serve as convenient pharmacodynamic read‑outs for genetic‑perturbation or small‑molecule compound screening targeting upstream Hippo‑pathway components.

Research Perspectives for Hippo‑Wnt Crosstalk in Intestinal Stem‑Cell and Tumour Biology

Collective mechanistic findings revise existing conceptual frameworks describing Hippo‑YAP‑TAZ signal transduction within intestinal epithelial systems. LATS1/2 maintains ISC pools by enabling Wnt‑transcriptional output through a TEAD‑independent YAP‑TAZ‑TLE‑TCF inhibitory circuit. Meanwhile, LATS1/2 restricts aberrant crypt expansion by limiting TEAD‑driven pro‑proliferative transcriptional responses.

These mechanistic discoveries open exploratory research avenues targeting TEAD palmitoylation‑dependent signalling for intestinal‑neoplasia‑relevant basic‑research. Reliable phospho‑site‑specific immunodetection reagents constitute essential experimental infrastructure for profiling pathway‑activation dynamics across diverse genetic and pharmacological perturbation experimental‑model‑systems.

Phospho‑LATS1/2 (Ser909/872) Recombinant Rabbit mAb Research Reagent from ANT BIO PTE. LTD

ANT BIO PTE. LTD provides Phospho‑LATS1/2 (Ser909/872) Recombinant Rabbit mAb (S0B1465), a phospho‑site‑specific antibody detecting activated LATS‑kinase signalling for Hippo‑pathway‑focused stem‑cell‑and‑tumour‑biology basic‑research assignments. Each antibody production lot undergoes epitope‑specificity screening and multi‑assay functional‑validation prior to commercial‑product release.

Catalog Table of Phospho‑LATS1/2 Research Antibody

Functional‑Validation Characteristics of ANT BIO PTE. LTD S0B1465 Antibody

S0B1465 selectively recognizes MST1/2‑mediated phosphorylated activation‑loop epitopes shared by LATS1 and LATS2 polypeptides, with minimal cross‑reactivity toward unphosphorylated LATS‑protein pools. Validated sample matrices include cultured epithelial‑cell lysates, mouse intestinal‑crypt tissue homogenates and pre‑clinical intestinal‑tumour‑model tissue specimens. Qualified experimental workflows encompass Western‑blot Hippo‑kinase‑activity quantification and immunofluorescence intracellular‑localization imaging for cell‑culture‑and‑tissue‑section‑derived biological‑specimens. The reagent exhibits consistent batch‑to‑batch performance supporting repeatable longitudinal signalling‑dynamic monitoring in basic‑research‑laboratory environments.

Core Fundamental‑Research Applications for Phospho‑LATS1/2 (Ser909/872) Antibody

1. Western‑blot quantification of LATS1/2 activation‑loop phosphorylation magnitude under varied cell‑density, mechanical‑stress or GPCR‑ligand stimulation experimental‑conditions

2. Immunofluorescence‑based profiling of endogenous phospho‑LATS1/2 spatial‑distribution within mouse intestinal crypt tissue sections for ISC‑niche signalling‑investigation

3. Biochemical read‑out for genetic‑perturbation assays assessing Hippo‑pathway cascade activity in Lats‑knock‑out / MST‑knock‑out isogenic cell‑model‑systems

4. Pharmacodynamic biomarker monitoring during small‑molecule compound screening campaigns targeting upstream Hippo‑signalling‑cascade kinase components

5. Mechanistic‑research dissecting Hippo‑Wnt‑pathway‑crosstalk in intestinal‑stem‑cell homeostasis and Apc‑mutant colorectal‑tumour pre‑clinical‑model‑systems

6. Orthogonal signal‑validation paired with phospho‑YAP (S127) detection for comprehensive evaluation of complete Hippo‑signalling‑cascade activation states

Global Manufacturing & Compliance Standards

S0B1465 antibody batches complete phospho‑peptide‑array epitope‑specificity profiling and multi‑platform functional‑performance‑verification prior to commercial‑product release. Manufacturing facilities adhere to ISO9001, ISO13485 and EU 98/79/EC certification specifications governing life‑science‑research‑reagent‑production‑protocols. In‑house application‑science teams supply detailed immuno‑assay‑SOP documents and curated Hippo‑intestinal‑stem‑cell‑signalling‑reference‑publication‑resources. The broader reagent ecosystem includes additional PTM‑detection antibodies, recombinant‑proteins and ELISA‑kits supporting comprehensive stem‑cell‑oncology multi‑omics‑research pipelines.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANT BIO PTE. LTD., we are committed to advancing life science research through high‑quality, reliable reagents and comprehensive solutions. Our specialized sub‑brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer‑centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.